XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives

Name	Symbol	Market	Type
SPDR S&P Telecom ETF	AMEX:XTL	AMEX	Exchange Traded Fund

Name

Symbol

Market

Type

SPDR S&P Telecom ETF

AMEX:XTL

AMEX

Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	-0.3912	-0.36%	109.53	110.60	109.0069	110.60	4,833	21:15:00

Price Change

% Change

Price

High Price

Low Price

Open Price

Traded

Last Trade

-0.3912

-0.36%

109.53

110.60

109.0069

110.60

4,833

21:15:00

XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives

28/01/2009 9:12am

PR Newswire (US)

SPDR S&P Telecom ETF (AMEX:XTL)
Historical Stock Chart

From Nov 2019 to Nov 2024

Click Here for more SPDR S&P Telecom ETF Charts.

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today announced an update to its December 8, 2008 press release regarding the Company's activities in seeking to acquire potential assets or to identify a company to merge into or with XTL. The Company is currently evaluating several merger proposals that have been presented to it by both US and foreign-based companies who operate in and outside of the healthcare space. These discussions are preliminary in nature, and consequently, the timing of and ability to consummate such a transaction cannot be predicted at this time, and the Company may still decide that the distribution of its remaining assets to the shareholders in a liquidation offers the best possible alternative to the shareholders. XTL has retained an investment banking firm to advise the Company in assessing these potential merger opportunities. Cautionary Statement Some of the statements included in this press release, particularly those anticipating future business prospects, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. In particular, we may not be able to consummate a merger transaction with any of the potential merger partners due to certain conditions that are likely to be required by our potential merger partners and regulatory authorities. In addition, our remaining cash resources are scarce and we may be delisted from NASDAQ, both of which may further limit our ability to remain an attractive merger candidate. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com/. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only. DATASOURCE: XTL Biopharmaceuticals Ltd. CONTACT: Ron Bentsur, Chief Executive Officer of XTL Biopharmaceuticals Ltd., +1-845-267-0707 ext. 224 Web Site: http://www.xtlbio.com/

	Real-time Prices	Level 2
London Stock Exchange
Chi-X Europe
BATS Europe
Aquis Exchange
FTSE Indices
Euronext
New York Stock Exchange
NASDAQ
American Stock Exchange
Dow Jones Indices
Forex
Precious Metal

London Stock Exchange
Advanced charts
Premium community
Data download

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

XTL SPDR S&P Telecom ETF